Overview
PASS syndrome is a rare, chronic-relapsing inflammatory disorder characterized by the concurrent presence of pyoderma gangrenosum, acne vulgaris, hidradenitis suppurativa, and spondyloarthritis, lacking specific biological or genetic markers 1.Diagnosis
Clinical criteria include the presence of four core features: pyoderma gangrenosum, acne vulgaris, hidradenitis suppurativa, and spondyloarthritis 1.
No specific laboratory or imaging tests definitively diagnose PASS syndrome; diagnosis is primarily clinical 1.Management
First-line treatments: Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and antibiotics for specific manifestations 1.
Adjunctive treatments: Tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors have been used, though efficacy varies 1.
Novel treatment: Secukinumab, an IL-17A inhibitor, showed remarkable clinical improvement in a case report, suggesting potential as a therapeutic option 1.Special Populations
Pregnancy: No specific data provided in the abstracts 1.
Pediatrics: No specific data provided in the abstracts 1.
Elderly: No specific data provided in the abstracts 1.
Comorbidities: Management considerations for comorbidities are not detailed in the provided abstracts 1.Key Recommendations
Consider TNF inhibitors and IL inhibitors as adjunctive therapies for managing PASS syndrome symptoms (Evidence: Moderate 1).
Secukinumab may be considered for patients with refractory symptoms, based on promising case study outcomes (Evidence: Weak 1).
Further randomized controlled trials are needed to establish definitive treatment guidelines for PASS syndrome (Evidence: Expert opinion 1).References
1 Li M, Xiang H, Liang Y, Xue L, Zhou X, Yang L et al.. Secukinumab for PASS syndrome: A new choice for therapeutic challenge?. Dermatologic therapy 2022. link